文献速递糖尿病

每周一次胰岛素icodec与每日一次基础胰岛素对2型糖尿病患者体力活动相关低血糖的影响:ONWARDS 1-5的事后分析

The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5.
PubMed 文献 · Diabetologia · 2025-04-05

该事后分析汇总ONWARDS 1-5五项随机对照试验,比较每周一次基础胰岛素icodec与每日一次基础胰岛素在2型糖尿病成人中体力活动相关低血糖的发生情况。结果显示,各试验中icodec与每日一次胰岛素在体力活动相关低血糖事件比例上无一致差异,体力活动相关临床显著或严重低血糖的比值比均无统计学显著差异;结论认为这些发现不提示icodec较每日一次基础胰岛素额外增加体力活动相关低血糖风险。

要点

  • ONWARDS 1-5事后分析比较icodec与每日一次基础胰岛素体力活动相关低血糖。
  • 各试验中两组体力活动相关低血糖事件比例无一致差异。
  • 体力活动相关临床显著或严重低血糖的比值比均无统计学显著差异。

核心结论

  • 这些发现不提示每周一次基础胰岛素icodec较每日一次基础胰岛素在2型糖尿病成人中额外增加体力活动相关低血糖风险。

研究设计与样本

  • ONWARDS 1-5为3a期随机对照试验,比较每周一次基础胰岛素icodec与每日一次基础胰岛素在胰岛素初治(ONWARDS 1、3、5)和胰岛素经治(ONWARDS 2、4)的2型糖尿病成人中的有效性和安全性。
  • 参与者使用血糖仪和数字日记自我监测血糖,怀疑低血糖症状时触发额外自我血糖测量并记录于数字日记,发生低血糖事件者被指导记录事件与体力活动的关联。
  • 低血糖事件分为警戒值(1级:血糖<3.9但≥3.0 mmol/l)、临床显著(2级:血糖<3.0 mmol/l)或严重(3级:认知障碍需外部援助)。
  • 对五项试验分别计算两种基础胰岛素类型(每周一次vs每日一次)体力活动相关低血糖事件的比例及发生体力活动相关低血糖事件的OR。

主要发现

  • 所有试验中,icodec与每日一次胰岛素对照在体力活动相关低血糖事件比例上无一致差异,这些事件主要为警戒值或临床显著低血糖事件。
  • 在胰岛素初治和胰岛素经治参与者中,ONWARDS 1、2、3和5的体力活动相关临床显著或严重低血糖发生率一致≤3.0%。
  • ONWARDS 4中两种治疗组体力活动相关低血糖发生率均数值更高(icodec 18.6% vs 甘精胰岛素U100 17.9%),原文认为鉴于基础-餐时胰岛素方案此为预期结果。
  • 所有试验中,icodec与每日一次胰岛素对照发生体力活动相关临床显著或严重低血糖事件的比值比均无统计学显著差异。
  • 体力活动相关临床显著或严重低血糖事件后24小时内复发性临床显著或严重低血糖频率低,ONWARDS 1、3和5无此类事件;ONWARDS 2和4中icodec较每日一次胰岛素对照复发性临床显著低血糖频率数值更高,所有试验中无参与者报告额外严重事件。

关键数值与推荐

  • 低血糖分级:1级警戒值血糖<3.9但≥3.0 mmol/l;2级临床显著血糖<3.0 mmol/l;3级严重认知障碍需外部援助。
  • ONWARDS 4体力活动相关低血糖发生率:icodec 18.6% vs 甘精胰岛素U100 17.9%。
  • ONWARDS 1、2、3和5体力活动相关临床显著或严重低血糖发生率一致≤3.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Physical activity increases the risk of hypoglycaemia in individuals with type 2 diabetes when basal or basal-bolus insulin therapy is administered. Once-weekly basal insulins may elevate the risk of physical activity-attributed hypoglycaemia compared with other basal insulins because the administered levels cannot be reduced in anticipation of increased physical activity. This post hoc analysis of five separate randomised trials (ONWARDS 1-5) aimed to examine physical activity-attributed hypoglycaemic episodes in adults with type 2 diabetes receiving either once-weekly basal insulin icodec (herein referred to as 'icodec') or once-daily basal insulins. METHODS: The ONWARDS 1-5 Phase 3a randomised controlled trials compared the efficacy and safety of once-weekly basal icodec vs once-daily basal insulin in insulin-naive (ONWARDS 1, 3 and 5) and insulin-experienced (ONWARDS 2 and 4) adults with type 2 diabetes. Participants self-monitored their blood glucose levels using a blood glucose meter and a digital diary. In each trial, suspected hypoglycaemia symptoms triggered additional self-measured blood glucose readings, and values indicative of hypoglycaemia were recorded in the participants' digital diary. Participants who experienced hypoglycaemic episodes were instructed to note any relation of each episode to physical activity. Hypoglycaemic episodes were classified as alert value (level 1: blood glucose <3.9 but ≥3.0 mmol/l), clinically significant (level 2: blood glucose <3.0 mmol/l) or severe (level 3: cognitive impairment requiring external assistance). The proportions of hypoglycaemic episodes that were attributed to physical activity and the ORs of having a physical activity-attributed hypoglycaemic episode were calculated for the two basal insulin types (once-weekly vs once-daily) for each of the five trials. RESULTS: Across all trials, there were no consistent differences between icodec and the once-daily insulin comparators in the proportions of hypoglycaemic episodes that were attributed to physical activity; these episodes were mainly alert value or clinically significant hypoglycaemic episodes. In both insulin-naive and insulin-experienced participants, the incidence of physical activity-attributed clinically significant or severe hypoglycaemic episodes was consistently ≤3.0% in ONWARDS 1, 2, 3 and 5. In ONWARDS 4, the incidence of physical activity-attributed hypoglycaemic episodes was numerically higher in both treatment groups (18.6% [icodec] vs 17.9% [insulin glargine U100]), which was expected given the basal-bolus insulin regimen. Across all trials, there were no statistically significant differences in the odds of experiencing a physical activity-attributed clinically significant or severe hypoglycaemic episode with icodec vs once-daily insulin comparators. The frequency of recurrent clinically significant or severe hypoglycaemic episodes in the 24 h after a physical activity-attributed clinically significant or severe hypoglycaemic episode was low, with no such episodes in ONWARDS 1, 3 and 5. In contrast, in ONWARDS 2 and 4, the frequency of recurrent clinically significant hypoglycaemic episodes in the 24 h after a physical activity-attributed clinically significant or severe hypoglycaemic episode was numerically higher with icodec vs the once-daily insulin comparators, whilst no additional severe episodes were reported in any participants across the trials. CONCLUSIONS/INTERPRETATION: These findings do not suggest that there is an additional increase in hypoglycaemia risk attributed to physical activity with once-weekly basal icodec vs once-daily basal insulins in adults with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04460885 (ONWARDS 1), NCT04770532 (ONWARDS 2), NCT04795531 (ONWARDS 3), NCT04880850 (ONWARDS 4) and NCT04760626 (ONWARDS 5).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Riddell MC, Heller S, Carstensen L, et al. The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5. Diabetologia. 2025. PMID: 40186685. doi:10.1007/s00125-025-06414-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。